CD274 and cancer: Targeting TDLNs with PD-L1 inhibitors induces enhanced anti-cancer T cell immunity and accelerates the infiltration of progenitor-exhausted T cells into the tumor, leading to improved tumor control in mice (30) (Figure 3).